Protocol Ledger

NCT05156398 · Phase III · RECRUITING

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Interventional Phase III clinical trial protocol NCT05156398 sponsored by Pfizer in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-28 Enrollment: 640 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05156398
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)640 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05156398
Protocol FieldVerified Registry Value
NCT IdentifierNCT05156398
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment640 participants (ESTIMATED)
Registered Start Date2022-02-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05156398
Hospital Research SiteLocationSite Profile
Velocity Clinical Research (La Mesa)La Mesa, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI